Cell-mediated and cell membrane-coated nanoparticles for drug delivery and cancer therapy

Yaman, Serkan; Chintapula, Uday; Rodríguez, Edgar Charry; Ramachandramoorthy, Harish; Nguyen, Kytai T.

doi:10.20517/cdr.2020.55

Cited by 30 publications

(38 citation statements)

References 177 publications

(254 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Cell membrane-coated NPs (CMCNPs) are biomimetic strategies developed to mimic the properties of cell membranes derived from natural cells such as erythrocytes, white blood cells, cancer cells, stem cells, platelets, or bacterial cells with an NP core. 161 Core NPs made of polymer, silica, and metal have been evaluated in attempts to overcome the limitations of conventional drug delivery systems but there are also issues of toxicity and reduced biocompatibility associated with the surface properties of NPs. 162 , 163 Therefore, only a small number of NPs have been approved for medical application by the FDA.…”

Section: Msc Mimicking Nanoencapsulation Targeting Arthritismentioning

confidence: 99%

Stem Cell Mimicking Nanoencapsulation for Targeting Arthritis

Shin¹,

Park²,

Lee³

et al. 2021

IJN

View full text Add to dashboard Cite

Mesenchymal stem cells (MSCs) are considered a promising regenerative therapy due to their ability to migrate toward damaged tissues. The homing ability of MSCs is unique compared with that of non-migrating cells and MSCs are considered promising therapeutic vectors for targeting major cells in many pathophysiological sites. MSCs have many advantages in the treatment of malignant diseases, particularly rheumatoid arthritis (RA). RA is a representative autoimmune disease that primarily affects joints, and secreted chemokines in the joints are well recognized by MSCs following their migration to the joints. Furthermore, MSCs can regulate the inflammatory process and repair damaged cells in the joints. However, the functionality and migration ability of MSCs injected in vivo still show insufficient. The targeting ability and migration efficiency of MSCs can be enhanced by genetic engineering or modification, eg, overexpressing chemokine receptors or migration-related genes, thus maximizing their therapeutic effect. However, there are concerns about genetic changes due to the increased probability of oncogenesis resulting from genome integration of the viral vector, and thus, clinical application is limited. Furthermore, it is suspected that administering MSCs can promote tumor growth and metastasis in xenograft and orthotopic models. For this reason, MSC mimicking nanoencapsulations are an alternative strategy that does not involve using MSCs or bioengineered MSCs. MSC mimicking nanoencapsulations consist of MSC membrane-coated nanoparticles, MSC-derived exosomes and artificial ectosomes, and MSC membrane-fused liposomes with natural or genetically engineered MSC membranes. MSC mimicking nanoencapsulations not only retain the targeting ability of MSCs but also have many advantages in terms of targeted drug delivery. Specifically, MSC mimicking nanoencapsulations are capable of encapsulating drugs with various components, including chemotherapeutic agents, nucleic acids, and proteins. Furthermore, there are fewer concerns over safety issues on MSC mimicking nanoencapsulations associated with mutagenesis even when using genetically engineered MSCs, because MSC mimicking nanoencapsulations use only the membrane fraction of MSCs. Genetic engineering is a promising route in clinical settings, where nano-encapsulated technology strategies are combined. In this review, the mechanism underlying MSC homing and the advantages of MSC mimicking nanoencapsulations are discussed. In addition, genetic engineering of MSCs and MSC mimicking nanoencapsulation is described as a promising strategy for the treatment of immune-related diseases.

show abstract

Section: Msc Mimicking Nanoencapsulation Targeting Arthritismentioning

confidence: 99%

Stem Cell Mimicking Nanoencapsulation for Targeting Arthritis

Shin¹,

Park²,

Lee³

et al. 2021

IJN

View full text Add to dashboard Cite

show abstract

“…It is worth noting that biomimetic nano-drug delivery systems such as RBCs membrane 37 , platelets membrane 38 , 39 , and macrophages membrane 40 , 41 coating strategies have been employed to prolong blood circulation time and target atherosclerosis sites. However, several technological issues remain to be addressed before this technology can be developed for therapies, including uneven and incomplete coating, short shelf life, and limited scalability 42 , 43 .…”

Section: Discussionmentioning

confidence: 99%

Inflammatory endothelium-targeted and cathepsin responsive nanoparticles are effective against atherosclerosis

Fang

et al. 2022

Theranostics

View full text Add to dashboard Cite

Rationale: Atherosclerosis is characterized by lipid accumulation, plaque formation, and artery stenosis. The pharmacological treatment is a promising therapy for atherosclerosis, but this approach faces major challenges such as targeted drug delivery, controlled release, and non-specific clearance. Methods: Based on the finding that the cathepsin k (CTSK) enzyme is enriched in atherosclerotic lesions, we constructed an integrin α v β 3 targeted and CTSK-responsive nanoparticle to control the release of rapamycin (RAP) locally. The targeted and responsive nanoparticles (T/R NPs) were engineered by the self-assembly of a targeting polymer PLGA-PEG-c(RGDfC) and a CTSK-sensitive polymer PLGA-Pep-PEG. PLGA-Pep-PEG was also modified with a pair of FRET probe to monitor the hydrolysis events. Results: Our results indicated that RAP@T/R NPs accelerated the release of RAP in response to CTSK stimulation in vitro , which significantly inhibited the phagocytosis of OxLDL and the release of cytokines by inflammatory macrophages. Additionally, T/R NPs had prolonged blood retention time and increased accumulation in the early and late stage of atherosclerosis lesions. RAP@T/R NPs significantly blocked the development of atherosclerosis and suppressed the systemic and local inflammation in ApoE -/- mice. Conclusions: RAP@T/R NPs hold a great promise as a drug delivery system for safer and more efficient therapy of atherosclerosis.

show abstract

“…Activated neutrophils hold great potential in cancer targeted drug delivery, having advantages similar to those of other immune cells, such as niche-targeting trafficking properties via intrinsic cell adhesion molecules on membranes [ 116 ]. Neutrophils also have distinct capabilities to travel to the brain and penetrate inflamed brain tumors which other cells cannot easily access [ 117 ]. For example, Xue et al reported that paclitaxel (PTX)-loaded neutrophils could suppress postoperative glioma recurrence [ 118 ].…”

Section: Mammalian Cell-based Ddssmentioning

confidence: 99%

Bioinspired and Biomimetic Nanomedicines for Targeted Cancer Therapy

Jin

2022

Pharmaceutics

View full text Add to dashboard Cite

Undesirable side effects and multidrug resistance are the major obstacles in conventional chemotherapy towards cancers. Nanomedicines provide alternative strategies for tumor-targeted therapy due to their inherent properties, such as nanoscale size and tunable surface features. However, the applications of nanomedicines are hampered in vivo due to intrinsic disadvantages, such as poor abilities to cross biological barriers and unexpected off-target effects. Fortunately, biomimetic nanomedicines are emerging as promising therapeutics to maximize anti-tumor efficacy with minimal adverse effects due to their good biocompatibility and high accumulation abilities. These bioengineered agents incorporate both the physicochemical properties of diverse functional materials and the advantages of biological materials to achieve desired purposes, such as prolonged circulation time, specific targeting of tumor cells, and immune modulation. Among biological materials, mammalian cells (such as red blood cells, macrophages, monocytes, and neutrophils) and pathogens (such as viruses, bacteria, and fungi) are the functional components most often used to confer synthetic nanoparticles with the complex functionalities necessary for effective nano-biointeractions. In this review, we focus on recent advances in the development of bioinspired and biomimetic nanomedicines (such as mammalian cell-based drug delivery systems and pathogen-based nanoparticles) for targeted cancer therapy. We also discuss the biological influences and limitations of synthetic materials on the therapeutic effects and targeted efficacies of various nanomedicines.

show abstract

Cell-mediated and cell membrane-coated nanoparticles for drug delivery and cancer therapy

Cited by 30 publications

References 177 publications

Stem Cell Mimicking Nanoencapsulation for Targeting Arthritis

Stem Cell Mimicking Nanoencapsulation for Targeting Arthritis

Inflammatory endothelium-targeted and cathepsin responsive nanoparticles are effective against atherosclerosis

Bioinspired and Biomimetic Nanomedicines for Targeted Cancer Therapy

Contact Info

Product

Resources

About